5-FU	5-fluorouracil
CA19-9	carbohydrate antigen 19-9
CAPOX	capecitabine plus oxaliplatin
CEA	carcinoembryonic antigen
CI	confidence interval
CR	complete response
CRC	colorectal cancer
CRS	cytoreductive surgery
ECOG	Eastern Cooperative Oncology Group
EGFR	epidermal growth factor receptor
FDG	fluorodeoxyglucose
FOLFIRI	5-FU plus leucovorin and irinotecan
FOLFOX	5-FU plus leucovorin and oxaliplatin
FOLFOXIRI	5-FU plus leucovorin, oxaliplatin, and irinotecan
HER2	human epidermal growth factor receptor 2
HIPEC	hyperthermic intraperitoneal chemotherapy
HR	hazard ratio
MMR	mismatch repair
ORR	objective response rate
OS	overall survival
PD	progressive disease
PET	positron emission tomography
PFS	progression-free survival
PR	partial response
SD	stable disease